Founded in 2021, Ray Therapeutics is a clinical-stage biotechnology company developing best-in-class vision restoration therapies for people with degenerative retinal diseases independent of genetic mutation. We use the innovative technology of optogenetics to reprogram surviving neurons in the retina of the eye to sense light and send visual signals to the brain—restoring vision.
We are advancing our pipeline of optogenetic medicines to address a range of degenerative retinal diseases, with programs in both preclinical and clinical stages of development. Ray Therapeutics’ lead candidate, RTX-015, is bioengineered to repurpose retinal ganglion cells to restore vision, and is being evaluated in a Phase 1 trial in Retinitis Pigmentosa and Choroideremia.
Company Details
- Employees
- 31
- Founded
- -
- Address
- 2607 7th St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.raytherapeutics.com
- Keywords
- jobs.
- HQ
- Berkeley, California
Ray Therapeutics, Inc. Questions
Ray Therapeutics, Inc.'s website is http://www.raytherapeutics.com
Ray Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/ray-therapeutics-inc
Ray Therapeutics, Inc. has
31 employees.
View email and phone details for 31
employees at Ray Therapeutics, Inc..
Ray Therapeutics, Inc.'s industry is
Biotechnology Research
Ray Therapeutics, Inc.'s top competitors are
Siren Biotechnology,
Arsenal Biosciences, Inc.,
Cargo Therapeutics,
Ascend Advanced Therapies,
Nanoscope Therapeutics Inc.,
Tenpoint Therapeutics Ltd,
Abalone Bio,
Gordian Biotechnology,
Beacon Therapeutics,
4d Molecular Therapeutics.
Ray Therapeutics, Inc.'s categories are Biotechnology Research
Ray Therapeutics, Inc.'s founding year is 2021
